您当前的位置: 首页 > 最新研究

最新研究共计 2,608 条信息

      全选  导出

1 Biospace,1月5日,Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA 2022-01-10

CHENGDU,China,Jan.05,2022(GLOBE NEWSWIRE)--Clover Biopharmaceuticals,Inc.,(Clover;Stock code:2197.HK),a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates,today announced that the first participants have been dosed with Clover’s COVID-19 vaccine candidate,SCB-2019(CpG 1018/Alum),as ahomologous booster dose following primary vaccination of SCB-2019(CpG 1018/Alum)in the ongoing global Phase 2/3 SPECTRA clinical trial.Clover reported final efficacy data for SCB-2019(CpG 1018/Alum)in SPECTRA in September 2021 and the study is continuing to generate additional immunogenicity and safety data. This double-blind,randomized,controlled study will evaluate the immunogenicity and safety of two formulations of SCB-2019(full dose:30µg with CpG 1018/Alum and half dose:15µg with CpG 1018/Alum)as ahomologous booster dose administered approximately 6months following 2-dose primary vaccination with SCB-2019(CpG 1018/Alum)in approximately 4,000 adult participants. In addition,the evaluation of the immunogenicity and safety of SCB-2019(CpG 1018/Alum)for primary vaccination in the adolescent(12-18 years)subgroup has been expanded to 1,200 adolescents.Initial data on both the homologous booster arm and adolescents are anticipated in the first half of 2022. 查看详细>>

来源: 点击量:180

2 Medicalxpress,1月4日,Early data for multivariant COVID-19 vaccine booster shows promise 2022-01-10

The first results of an early trial of amultivariant COVID-19 vaccine booster,launched in Manchester in September 2021,has shown it is driving acomprehensive immune response. U.S.-based biotechnology company Gritstone bio,Inc.in collaboration with The University of Manchester and Manchester University NHS Foundation Trust today(4 January 2022)reveal the initial phase one clinical data shows the vaccine has strong levels of neutralizing antibodies,similar to approved mRNA vaccines,but at up to a10-fold lower dose in the first 10 individuals. Results also show the vaccine,which is being trialed with the anticipated involvement of 20 people aged 60 and over,who were in good health and previously received two doses of AstraZeneca's first-generation COVID-19 vaccine,was generally safe and well-tolerated. Part of Gritstone's CORAL program,the compound is aself-amplifying mRNA second generation SARS-CoV-2 vaccine—or samRNA for short—which delivers antigens from both spike and non-spike proteins. The samRNA vaccine also produced broad CD8+T cell responses against targets from conserved SARS-CoV-2 viral proteins and boosted spike-specific Tcells. Based on results,the trial is now being expanded to 120 people,potentially enabling more rapid advancement into alater stage trial. 查看详细>>

来源: 点击量:63

3 Cell,1月3日,SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses 2022-01-10

On the 24th November 2021 the sequence of anew SARS CoV-2 viral isolate Omicron-B.1.1.529 was announced,containing far more mutations in Spike(S)than previously reported variants.Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha,Beta,Gamma,Delta are substantially reduced or fail to neutralize.Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta.Mutations in Omicron knock out or substantially reduce neutralization by most of alarge panel of potent monoclonal antibodies and antibodies under commercial development.Omicron Shas structural changes from earlier viruses,combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape,leading to alarge number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses. 查看详细>>

来源: 点击量:63

4 Medicalxpress,12月30日,Research team discovers a novel vaccine strategy to prevent SARS-CoV-2 nasal infection 2022-01-10

Researchers at the Department of Microbiology and State Key Laboratory of Emerging Infectious Diseases,LKS Faculty of Medicine of The University of Hong Kong(HKUMed)have conducted acomprehensive study for identifying an effective vaccine regimen in preventing SARS-CoV-2 nasal infection.The study demonstrated that acombination of intramuscular PD1-based receptor-binding domain(RBD)DNA vaccine(PD1-RBD-DNA)prime and intranasal live attenuated influenza-based vaccine(LAIV-HK68-RBD)boost vaccination regimen induced the strongest mucosal broadly neutralizing antibodies and lung resident memory CD8 Tcells,which prevented live SARS-CoV-2 nasal challenges in two animal models.The full research article is now online in the journal of EBioMedicine,published by The Lancet. 查看详细>>

来源: 点击量:61

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190